|
Type of FA | Age | | Prebiotic/probiotic | Form of administration | Doses | Main result | Reference |
|
CMA | 10-25 months | 12 | Lactobacillus rhamnosus GG | Extensively hydrolyzed commercial milk formula supplement | N/A | Enriched fecal microbiota with LGG formula consumption | [110] |
CMA | 4-6 years | 330 | Lactobacillus rhamnosus GG | Extensively hydrolyzed commercial formula | LGG to CFU/g | Less functional dyspepsia, functional constipation, and functional abdominal pain in children with probiotics | [111] |
CMA | 1-12 months | 220 | Lactobacillus rhamnosus GG | Extensively hydrolyzed commercial formula | N/A | Less allergy-associated symptoms and faster tolerance acquisition at 12, 24, and 36 months | [112] |
CMA | 1-12 months | 39 | Lactobacillus rhamnosus GG | Extensively hydrolyzed commercial formula | CFU by gram of powder | Higher production of butyrate and related to higher production of butyrate in tolerant patients | [113] |
Peanut allergy | 1-10 years | 62 children | Coadministration of Lactobacillus rhamnosus CGMCC 1.3724 (NCC4007) and oral immunotherapy with peanuts | Lyophilized powder | CFU once a day together with peanut OIT for 18 months | Reduced peanut sensitization in combination with immunotherapy | [106] |
CMA | <6 months | 119 | Lactobacillus casei CRL431 and Bifidobacterium lactis Bb-12 | Extensively hydrolyzed commercial formula | N/A | No differences were observed regarding severity of atopic dermatitis | [114] |
CMA | <1 year | 260 | Lactobacillus rhamnosus GG | Extensively hydrolyzed commercial formula | N/A | Earlier acquisition of tolerance in supplemented children | [103] |
CMA | 3-12 months | 60 | Bifidobacterium lactis BB-12 and Streptococcus thermophilus TH-4 | Extensively hydrolyzed commercial formula | Bifidobacterium lactis BB-12 ( CFU) and Streptococcus thermophilus TH-4 ( CFU) | Reduced clinical symptoms with supplementation | [115] |
CMA | 0-12 months | 26 | Lactobacillus rhamnosus GG | Extensively hydrolyzed commercial formula | to CFU/g | Higher decrease of calprotectin and reduction of fecal hematochezia in supplemented participants | [116] |
CMA | <6 months | 111 | Lactobacillus casei CRL431 (Lactobacillus paracasei subspecies paracasei) and Bifidobacterium lactis Bb-12 | Extensively hydrolyzed formula | colony-forming units/g formula for each of the probiotic bacteria used | No difference was observed in the age of acquisition of allergen tolerance | [104] |
|